HC Wainwright Reiterates “Buy” Rating for Kamada (NASDAQ:KMDA)

Kamada (NASDAQ:KMDA)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They currently have a $11.00 target price on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 89.33% from the stock’s previous close. HC Wainwright also issued estimates for Kamada’s Q4 2024 earnings at $0.05 EPS, FY2025 earnings at $0.26 EPS, FY2026 earnings at $0.38 EPS, FY2027 earnings at $0.45 EPS and FY2028 earnings at $0.53 EPS.

Separately, StockNews.com cut shares of Kamada from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 27th.

Kamada Trading Down 0.9 %

Shares of KMDA stock opened at $5.81 on Thursday. Kamada has a 1-year low of $4.60 and a 1-year high of $6.53. The stock has a market cap of $333.96 million, a price-to-earnings ratio of 20.75 and a beta of 1.05. The stock has a 50-day moving average of $5.48 and a 200-day moving average of $5.47.

Kamada (NASDAQ:KMDA) last released its earnings results on Wednesday, August 14th. The biotechnology company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. The business had revenue of $42.47 million during the quarter, compared to the consensus estimate of $39.70 million. Kamada had a net margin of 9.92% and a return on equity of 6.36%. Sell-side analysts forecast that Kamada will post 0.26 earnings per share for the current year.

Institutional Investors Weigh In On Kamada

Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its holdings in shares of Kamada by 8.2% during the first quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock valued at $7,433,000 after purchasing an additional 100,800 shares during the period. Y.D. More Investments Ltd increased its position in Kamada by 1,956.0% in the 2nd quarter. Y.D. More Investments Ltd now owns 726,161 shares of the biotechnology company’s stock valued at $3,643,000 after buying an additional 690,842 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new position in Kamada during the 3rd quarter worth approximately $77,000. Finally, Plato Investment Management Ltd bought a new position in Kamada in the third quarter worth approximately $117,000. 20.38% of the stock is currently owned by institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.